Deep Tech Capital Movements Vol. 10

Weekly tracking of funding rounds, new funds, and strategic shifts in deep tech.

Welcome back to Deep Tech Capital Moments! Every week, we track funding rounds, new funds, and major strategic moves in deep tech

💡 Got a big deal to share? If your fund just backed something game-changing—or your startup just raised—let’s make sure the right people see it.

✨ For more, see Membership | DeepTech Catalyst | DeepTech Briefing | Venture Guides

Deep Tech Capital Movements is the only newsfeed fully dedicated to deep tech deals—saving you time and keeping you focused on what truly matters.

If you’re in deep tech—whether you’re building, investing, or simply staying ahead—you need to know where the capital is flowing.

This week, we tracked over 50 funding rounds, spanning pre-seed experiments, infrastructure-scale seed plays, and high-conviction Series A–C bets—allocating more than $1.2 billion toward the foundational technologies of the next industrial cycle.

The biotechnology sector emerged as the primary magnet for capital, capturing more than $330M in aggregate. Late-stage rounds into programmable biologics, ion channel therapeutics, and AI-driven drug discovery platforms indicate that the convergence between life sciences and computational infrastructure is maturing into a defined asset class. These companies are not operating at the fringes of pharma—they are redefining therapeutic pipelines with models that integrate neural mapping, high-throughput screening, and biofabrication. Notably, multiple Series B and C rounds in this vertical signal increased institutional confidence in the clinical and commercial viability of next-generation biologics.

Robotics and AI-enabled physical systems followed, with over